PRODUCT INFORMATION



Pertussis Toxin (islet-activating protein)

Item No. 19546

Overview and Properties

CAS Registry No.:	70323-44-3
Storage:	2-8°C (as supplied)
Stability:	≥2 years
Purity:	≥95% estimated by SDS-PAGE
Supplied in:	Each vial, when reconstituted to 500 μl with water, contains 50 μg of pertussis toxin in
	in 0.01 M sodium phosphate, 0.05 M sodium chloride, pH 7.0

Special Conditions: Handle gently; do not vortex; do not freeze Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

Pertussis toxin (islet-activating protein) is a toxin, first isolated from B. pertussis, that is used to study G protein-coupled receptor signaling in cells and experimental autoimmune encephalomyelitis (EAE) in animals. Pertussis toxin catalyzes the transfer of the ADP-ribose moiety of NAD to the α subunits of heterotrimeric G_{i/o} proteins, resulting in the receptors being uncoupled from G_{i/o} proteins.^{1,2} Pertussis toxin is also used as an adjuvant, given with specific antigens, to immunize animals and induce EAE, an animal model of multiple sclerosis.^{3,4} Pertussis toxin was first described as an islet-activating protein because it caused a sustained potentiation of the secretory response of pancreatic islet cells to various stimuli that stimulate G_i-linked α-adrenergic receptors.^{5,6}

References

- 1. Kaslow, H.R. and Burns, D.L. Pertussis toxin and target eukaryotic cells: Binding, entry, and activation. FEBS J. 6(9), 2684-2690 (1992).
- 2. Ui, M. Islet-activating protein, pertussis toxin: A probe for functions of the inhibitory guanine nucleotide regulatory component of adenylate cyclase. Trends Pharmacol. Sci. 5, 277-279 (1984).
- 3. Hofstetter, H.H., Shive, C.L., and Forsthuber, T.G. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: Induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169(1), 117-125 (2002).
- 4. Ronchi, F., Basso, C., Preite, S., et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1ß production by myeloid cells. Nat. Commun. 7:11541, (2016).
- 5. Heyworth, C.M., Grey, A.-M., Wilson, S.R., et al. The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes. Biochem. J. 235(1), 145-149 (1986).
- 6. Katada, T. and Michio, U. Slow interaction of islet-activating protein with pancreatic islets during primary culture to cause reversal of α-adrenergic inhibition of insulin secretion. J. Biol. Chem. 255(20), 9580-9588 (1980).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 02/10/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM